TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06226376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.
Study: NCT05212974

Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.

Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
Study: NCT06100926

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: software
Description: virtual reality scene

Intervention type: DEVICE
Group type: OTHER
Intervention: software
Description: virtual reality scene
Study: NCT06010589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1558
Description: DWJ1558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202310 and DWC202311
Description: Co-administration of DWC202310 and DWC202311
Study: NCT05409131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnipod 5 System
Description: Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
Study: NCT05369585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63
Description: 5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
Study: NCT05957107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.
Study: NCT06515340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose Dose 1
Description: 5 gram consumed orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose Dose 2
Description: 10 gram consumed orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose Dose 3
Description: 20 gram consumed orally
Study: NCT05349331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Resection
Description: Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
Study: NCT06140615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of lungs
Study: NCT05649631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: 50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: 50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
Study: NCT05888207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
Study: NCT05614999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy training curriculum
Description: Eight sessions training in endoscopic tip control using Varix trainer model I.
Study: NCT06458686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Vitamin D is a fat soluble vitamin used for the treatment of many diseases.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a non drug formulation
Study: NCT05258305

Intervention type: DEVICE
Group type: OTHER
Intervention: AuraGen 1-2-3 with AuraClens
Description: Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.

Intervention type: DEVICE
Group type: OTHER
Intervention: AuraGen 1-2-3 with AuraClens
Description: Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
Study: NCT04997252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: apalutamide as neoadjuvant therapy
Study: NCT05994339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
Study: NCT05104437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine (0-1-4 schedule)
Description: Subjects receive the booster vaccine 3 months after the second dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid-19 vaccine (0-1-6 schedule)
Description: Subjects receive the booster vaccine 5 months after the second dose.
Study: NCT05350254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic maintenance care
Description: Manual Therapy, individual exercises and lifestyle advice
Study: NCT05005975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study: NCT05350254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard chiropractic care
Description: Standard care based on clinician's judgement
Study: NCT05846516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP154
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP154
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP154
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP150
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP150
Description: Injection
Study: NCT05279326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual SMAs
Description: 18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
Study: NCT04745780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin
Description: Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Two-times daily on an empty stomach, for 6 months
Study: NCT05801354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric Gel
Description: Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
Study: NCT05086120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eCARIBOU
Description: A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
Study: NCT05846516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP150
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP152
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP152
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP152
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Infusion
Study: NCT04994769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Capsule
Description: Epitomee Capsule combined with lifestyle counseling.
Study: NCT05487443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
Description: Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
Study: NCT04273347

Intervention type: OTHER
Intervention: standard of care for patient with brain trauma and spinal cord injury
Description: neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy

Intervention type: OTHER
Intervention: standard of care for patient with brain trauma and spinal cord injury
Description: neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
Study: NCT05318729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration tool
Description: Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
Study: NCT04686448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-ketamine
Description: patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Study: NCT04971889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes MNT
Description: Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes MNT
Description: Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
Study: NCT06431360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermia
Description: hyperthermia (using a heater, 44℃for 15 min)
Study: NCT05097183

Intervention type: PROCEDURE
Intervention: Accurate Commissural Alignment (ACA)
Description: Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
Study: NCT05426655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management
Description: The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held.
Study: NCT06023745

Intervention type: GENETIC
Intervention: genotyping
Description: Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.

Intervention type: GENETIC
Intervention: genotyping
Description: Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
Study: NCT05418478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention transtheoretical model group
Description: The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change).
Study: NCT06529198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroGyn Genital Neuromodulation System
Description: Genital Neuromodulation
Study: NCT05302284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70mg/m2 IV infusion on Day 1 of every 3 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=4.5, IV infusion on Day 1 of every 3 week cycle
Study: NCT05626010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 300mg iv dripping at end of surgery
Study: NCT06101966

Intervention type: RADIATION
Intervention: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
Description: Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
Study: NCT04686448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-fentanyl
Description: patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
Study: NCT05201287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Disc NP
Description: VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Study: NCT04380831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Undergo HSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TBI using IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI using IMRT
Study: NCT06161740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle strengthening
Description: The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle strengthening
Description: The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
Study: NCT05827783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Bee Buzzy
Description: Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of Puppet Zuzu
Description: Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure.
Study: NCT04396483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pomeroy's tubal sterilization
Description: Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Both fallopian tubes will be completely removed during cesarean section